Spectrum's EOquin/irradiation combo slows tumor growth more than either used alone, study shows

By Angela McDaniels

Seattle, Nov. 15 - Spectrum Pharmaceuticals Inc. said clinical data suggests that its EOquin, when combined with irradiation, slows tumor growth more efficiently than either radiation alone or the drug alone.

The study was conducted to investigate the expression of bioreductive enzymes in hypoxic tumors and to explore EOquin as a potential radiation sensitizer, the company said.

The study led by Randy Burd from the University of Arizona, Tucson, with colleagues from the Thomas Jefferson University in Philadelphia.

The data was presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications Meeting in Philadelphia.

EOquin, a pro-drug, becomes a cytotoxic alkylating agent in the presence of an enzyme that is present in greater amounts in hypoxic cancer cells.

Spectrum Pharmaceuticals is an Irvine, Calif.-based pharmaceutical company that develops prescription drug products for the treatment of cancer and other unmet medical needs.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.